Insider and Congress filings

Intellia Therapeutics, Inc. (NTLA)

Biotechnology, listed on NASDAQ.

24 insider transactions10 Congress tradeslast filed Nov 3, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

EarningsQ3 FY2026 · reported Nov 5, 2026

Intellia Therapeutics missed by 26.5% on revenue.

Revenue $7.16M against a $9.74M consensus. EPS was -$0.91 a share under GAAP; the -$0.80 consensus is for adjusted EPS.

Revenue

Reported$7.16M
Consensus$9.74M

Beat 4In line 1Miss 1

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Next report Feb 25, 2027. Consensus -$0.77 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

2

of the 97 fund managers GetSignal tracks list Intellia Therapeutics among their largest positions. Cathie Wood held the most, $285.5M.

Tracked managers’ Q2 2026 moves

RA Capitalopened+$76.6M

Each manager’s 13F against the one before, priced at the Jun 30, 2026 close: an estimate, from each manager’s 15 largest moves. Not investment advice.

Every manager

Insider tradesForm 4 · 7 open-market filings shown

Seven open-market sales, 4 of them under 10b5‑1 plans.

Jul 1, 2026Nov 2, 2026

SalesSales under a plan

4 of 7 under a plan

A median 2 business days from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 11, 2026

About Intellia Therapeutics, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Chief executive
John Leonard
Employees
377
Listed since
May 6, 2016
Market value
$1.6B
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$3.04
Dividend yield
-

www.intelliatx.com

GetSignal News2 articles · newest first

GetSignal News

HeadlineSourceDate
Intellia Therapeutics presents additional lonvo-z data at ACAAI 2026Intellia Therapeutics also plans an investor webcast on November 12, 2026, at 10:00 a.m. ET on the data and its launch preparations.Company releaseNov 12, 2026
Intellia Therapeutics grants inducement awards to three new employeesThe awards were made November 1, 2026, under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.Company releaseNov 6, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

Company news from every company we cover

Earnings6 reported quarters · next on Feb 25, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Nov 5, 2026-$0.91-$0.80$7.2M$9.7MEPS miss, GAAPRevenue miss
Q2 FY2026reported Aug 6, 2026-$0.80-$0.80$7.7M$13.0MEPS in line, GAAPRevenue miss
Q1 FY2026reported May 11, 2026-$0.81-$0.92$15.0M$13.8MEPS beat, GAAPRevenue beat
Q4 FY2025reported Feb 26, 2026-$0.83-$0.99$23.0M$12.0MEPS beatRevenue beat
Q3 FY2025reported Nov 6, 2025-$0.92-$1.02$13.8M$12.2MEPS beat, GAAPRevenue beat
Q2 FY2025reported Aug 7, 2025-$0.99-$1.03$14.2M$14.1MEPS beat, GAAPRevenue in line

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on NTLA yet. Briefs from every company we cover.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on NTLA, newest first
FirmRatingTargetActionDate
BarclaysUnderweight$8Initiated
WedbushNeutral$13Target set
Evercore ISIOutperform$24Target set
Wolfe ResearchUnderperform$9Target set
BernsteinMarket Perform$17Target set
ChardanBuy$30Target set
Morgan StanleyEqual Weight$15Target set
BairdNeutral$13Raised from $7
H.C. WainwrightBuy$25Target set

Each firm's latest target from the past year, with the rating stated with its note or within three days of it. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

7 other firms rated NTLA in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 12, 2026.

Proxy statementas filed for fiscal 2025 · proxy filed Apr 30, 2026

Executive pay

John M. Leonard, M.D.’s pay as CEO came to $5.1M for fiscal 2025.
ExecutiveSalaryStock awardsOtherTotal
John M. Leonard, M.D.President, Chief Executive Officer$708K$2.4M$1.9M$5.1M
Edward J. Dulac IIIExecutive Vice President, Chief Financial Officer and Treasurer$526K$848K$794K$2.2M
David Lebwohl, M.D.Executive Vice President, Chief Medical Officer$536K$776K$672K$2.0M
James Basta, J.D.Executive Vice President, General Counsel and Corporate Secretary$494K$719K$634K$1.8M
Birgit Schultes, Ph.D.Executive Vice President, Chief Scientific Officer$475K$676K$589K$1.7M

The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

330 institutions reported Intellia Therapeutics shares in 13F filings for Jun 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
ARK Investment Management LLCCathie Wood$285.5M16,875,684+16.3%12.64%
BlackRock, Inc.$260.7M15,409,023+26.8%11.54%
State Street Corp$156.3M9,234,987+33.4%6.92%
Vanguard Portfolio Management LLC$124.1M7,332,401+17.8%5.49%
D. E. Shaw & Co., Inc.$109.0M6,443,323+12.5%4.83%
Vanguard Capital Management LLC$102.0M6,028,586+18.6%4.52%
Two Sigma Investments, LP$88.6M5,235,348+11.3%3.92%
FMR LLC$80.8M4,773,034+130.9%3.58%
RA Capital Management, L.P.$76.6M4,526,926New3.39%
Regeneron Pharmaceuticals, Inc.$62.7M3,702,9950.0%2.77%
Geode Capital Management, LLC$61.4M3,631,061+27.3%2.72%
Arrowstreet Capital, Limited Partnership$55.5M3,280,760+134.8%2.46%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings2 managers

Tracked fund managers holding NTLA

ManagerValueSharesShare of book
Cathie WoodARK Invest$285.5M16,875,6841.9%
RA Capital ManagementPeter Kolchinsky$76.6M4,526,9260.7%

2 of the 97 fund managers we track list NTLA shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 47 filings shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
John M. LeonardPresident and CEOSold · scheduled9,000$11.99$108KNov 2, 2026filed Nov 3, 20261d
Michael P. DubeVP, Chief Accounting OfficerSold1,864$12.43$23KOct 2, 2026filed Oct 6, 20262d
John M. LeonardPresident and CEOSold · scheduled2,785$13.00$36KAug 21, 2026filed Aug 24, 20261d
John M. LeonardPresident and CEOSold · scheduled19,890$12.60$251KAug 20, 2026filed Aug 24, 20262d
Edward J. Dulac IIIEVP, Chief Financial OfficerSold8,111$11.25$91KJul 22, 2026filed Jul 24, 20262d
Edward J. Dulac IIIEVP, Chief Financial OfficerSold · scheduled4,677$18.00$84KJul 2, 2026filed Jul 6, 20261d
Michael P. DubeVP, Chief Accounting OfficerSold2,641$16.78$44KJul 1, 2026filed Jul 6, 20262d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (9)
InsiderEventSharesDate
Jing L. MarantzEVP, Chief Medical OfficerStock award474,883Oct 26, 2026
Muna BhanjiDirectorStock award22,500Jun 9, 2026
William J. ChaseDirectorStock award22,500Jun 9, 2026
Fred E. CohenDirectorStock award22,500Jun 9, 2026
Brian GoffDirectorStock award22,500Jun 9, 2026
Jesse GoodmanDirectorStock award22,500Jun 9, 2026
Georgia KerestyDirectorStock award22,500Jun 9, 2026
Frank VerwielDirectorStock award22,500Jun 9, 2026
John M. LeonardPresident and CEOStock award156,400Mar 1, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act10 disclosures of 10 on record · median 12d of the 45 allowed

Congress trades in NTLA

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Donald S. Beyer, Jr.JointStockSale$15,001 - $50,000-88.5% since the saleEstimated exit price $98.85, close on Mon Feb 28, 2022Current price $11.41, close on Wed Nov 11Feb 28, 2022Mar 3, 20223d
Donald S. Beyer, Jr.JointStockSale$1,001 - $15,000-91.4% since the saleEstimated exit price $132.98, close on Fri Oct 29, 2021Current price $11.41, close on Wed Nov 11Oct 29, 2021Oct 30, 20211d
Donald S. Beyer, Jr.JointStockSale$1,001 - $15,000-92.3% since the saleEstimated exit price $148.36, close on Mon Sep 20, 2021Current price $11.41, close on Wed Nov 11Sep 20, 2021Oct 1, 202111d
Donald S. Beyer, Jr.JointStockSale$1,001 - $15,000-92.5% since the saleEstimated exit price $152.75, close on Wed Jul 21, 2021Current price $11.41, close on Wed Nov 11Jul 21, 2021Aug 7, 202117d
Donald S. Beyer, Jr.JointStockSale$1,001 - $15,000-86.1% since the saleEstimated exit price $81.89, close on Fri Jan 15, 2021Current price $11.41, close on Wed Nov 11Jan 15, 2021Jan 31, 202116d
Donald S. Beyer, Jr.JointStockPurchase$1,001 - $15,000-66.7% since the tradeEstimated entry price $34.23, close on Wed Nov 18, 2020Current price $11.41, close on Wed Nov 11Nov 18, 2020Dec 1, 202013d
Donald S. Beyer, Jr.JointStockSale$1,001 - $15,000-45.0% since the saleEstimated exit price $20.75, close on Wed Aug 26, 2020Current price $11.41, close on Wed Nov 11Aug 26, 2020Sep 6, 202011d
Donald S. Beyer, Jr.JointStockPurchase$1,001 - $15,000-52.1% since the tradeEstimated entry price $23.81, close on Fri Jul 10, 2020Current price $11.41, close on Wed Nov 11Jul 10, 2020Aug 9, 202030d
Donald S. Beyer, Jr.JointStockPurchase$1,001 - $15,000-21.4% since the tradeEstimated entry price $14.52, close on Tue Jan 14, 2020Current price $11.41, close on Wed Nov 11Jan 14, 2020Feb 22, 202039d
Donald S. Beyer, Jr.JointStockPurchase$1,001 - $15,000-31.8% since the tradeEstimated entry price $16.72, close on Mon Dec 9, 2019Current price $11.41, close on Wed Nov 11Dec 9, 2019Dec 14, 20195d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

Every Congress trade in NTLA filterable by party, chamber, type and account.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 12, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on NTLA show and how current they are.

Are insiders buying or selling NTLA?

Across the 7 most recent open-market filings shown here, 0 were purchases and 7 were sales. 4 were scheduled in advance under a Rule 10b5-1 plan.

Which members of Congress have traded NTLA?

Donald S. Beyer, Jr. disclosed NTLA transactions in the filings shown here.

How quickly are NTLA trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 12 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track